Back to Search
Start Over
Clinical factors of post-chemoradiotherapy as valuable indicators for pathological complete response in locally advanced rectal cancer
- Source :
- Clinics; v. 71 n. 8 (2016); 449-454, Clinics; Vol. 71 Núm. 8 (2016); 449-454, Clinics; Vol. 71 No. 8 (2016); 449-454, Clinics, Universidade de São Paulo (USP), instacron:USP, Clinics, Vol 71, Iss 8, Pp 449-454, Clinics, Volume: 71, Issue: 8, Pages: 449-454, Published: AUG 2016
- Publication Year :
- 2016
- Publisher :
- Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo, 2016.
-
Abstract
- OBJECTIVES: Pathological complete response has shown a better prognosis for patients with locally advanced rectal cancer after preoperative chemoradiotherapy. However, correlations between post-chemoradiotherapy clinical factors and pathologic complete response are not well confirmed. The aim of the current study was to identify post-chemoradiotherapy clinical factors that could serve as indicators of pathologic complete response in locally advanced rectal cancer. METHODS: This study retrospectively analyzed 544 consecutive patients with locally advanced rectal cancer treated at Sun Yat-sen University Cancer Center from December 2003 to June 2014. All patients received preoperative chemoradiotherapy followed by surgery. Univariate and multivariate regression analyses were performed to identify post-chemoradiotherapy clinical factors that are significant indicators of pathologic complete response. RESULTS: In this study, 126 of 544 patients (23.2%) achieved pathological complete response. In multivariate analyses, increased pathological complete response rate was significantly associated with the following factors: post-chemoradiotherapy clinical T stage 0-2 (odds ratio=2.098, 95% confidence interval=1.023-4.304, p=0.043), post-chemoradiotherapy clinical N stage 0 (odds ratio=2.011, 95% confidence interval=1.264-3.201, p=0.003), interval from completion of preoperative chemoradiotherapy to surgery of >;7 weeks (odds ratio=1.795, 95% confidence interval=1.151-2.801, p=0.010) and post-chemoradiotherapy carcinoembryonic antigen ≤2 ng/ml (odds ratio=1.579, 95% confidence interval=1.026-2.432, p=0.038). CONCLUSIONS: Post-chemoradiotherapy clinical T stage 0-2, post-chemoradiotherapy clinical N stage 0, interval from completion of chemoradiotherapy to surgery of >;7 weeks and post-chemoradiotherapy carcinoembryonic antigen ≤2 ng/ml were independent clinical indicators for pathological complete response. These findings demonstrate that post-chemoradiotherapy clinical factors could be valuable for post-operative assessment of pathological complete response.
- Subjects :
- Male
Pathological Complete Response
Time Factors
Colorectal cancer
medicine.medical_treatment
Gastroenterology
0302 clinical medicine
Reference Values
Odds Ratio
Postoperative Period
Child
Neoadjuvant therapy
Aged, 80 and over
lcsh:R5-920
Chemoradiotherapy
General Medicine
Middle Aged
Clinical Science
Neoadjuvant Therapy
Treatment Outcome
030220 oncology & carcinogenesis
Preoperative Period
preoperative chemoradiotherapy
Female
030211 gastroenterology & hepatology
lcsh:Medicine (General)
Adult
medicine.medical_specialty
Adolescent
Adenocarcinoma
Rectal Cancer
Young Adult
03 medical and health sciences
Internal medicine
medicine
Humans
rectal cancer
Aged
Neoplasm Staging
Retrospective Studies
Rectal Neoplasms
business.industry
Preoperative Chemoradiotherapy
Cancer
Retrospective cohort study
Odds ratio
prediction
medicine.disease
Confidence interval
Surgery
Logistic Models
Multivariate Analysis
pathological complete response
T-stage
Prediction
business
Subjects
Details
- Language :
- English
- ISSN :
- 19805322 and 18075932
- Database :
- OpenAIRE
- Journal :
- Clinics; v. 71 n. 8 (2016); 449-454, Clinics; Vol. 71 Núm. 8 (2016); 449-454, Clinics; Vol. 71 No. 8 (2016); 449-454, Clinics, Universidade de São Paulo (USP), instacron:USP, Clinics, Vol 71, Iss 8, Pp 449-454, Clinics, Volume: 71, Issue: 8, Pages: 449-454, Published: AUG 2016
- Accession number :
- edsair.doi.dedup.....749cb4fded06d915606e565cac401267